Produktinformation
- (+)-Larixol
- (αS,1S,4S,4aS,8aR)-α-Ethenyldecahydro-4-hydroxy-α,5,5,8a-tetramethyl-2-methylene-1-naphthalenepropanol
- 1-Naphthalenepropanol, alpha-ethenyldecahydro-4-hydroxy-alpha,5,5,8a-tetramethyl-2-methylene-, [1S-[1alpha(R),4beta,4abeta,8aalpha]]-
- 1-Naphthalenepropanol, α-ethenyldecahydro-4-hydroxy-α,5,5,8a-tetramethyl-2-methylene-, (αS,1S,4S,4aS,8aR)-
- 1-Naphthalenepropanol, α-ethenyldecahydro-4-hydroxy-α,5,5,8a-tetramethyl-2-methylene-, [1S-[1α(R*),4β,4aβ,8aα]]-
- 4-(3-Hydroxy-3-methyl-4-pentenyl)-4a,8,8-trimethyl-3-methylenedecahydro-1-naphthalenol
- Labda-8(20),14-diene-6alpha,13-diol, (13S)-
- Labda-8(20),14-diene-6α,13-diol, (13S)-
- [(1S,4S,4aR,8aS)-4-[(3S)-3-acetoxy-3-methyl-pent-4-enyl]-4a,8,8-trimethyl-3-methylene-decalin-1-yl] acetate
Larixol acts as both an fMLP inhibitor and a modulator of various signaling pathways by inhibiting Src kinase, ERK1/2, p38, and AKT phosphorylation critical for immune responses. It disrupts the interaction between the βγ subunit of the Gi protein and downstream effectors linked to the fMLP receptor, thus abrogating fMLP-induced respiratory bursts. Additionally, larixol effectively reduces fMLP (0.1 μM)-triggered superoxide anion generation (IC50: 1.98 μM), cathepsin G secretion (IC50: 2.76 μM), and cellular chemotaxis, mitigating neutrophil hyperactivation and subsequent inflammation or tissue injury. Derivatives of larixol also demonstrate inhibitory activity on TRPC6 functional mutants associated with FSGS [1] [2].
Chemische Eigenschaften
Technische Anfrage zu: TM-T80653 Larixol
Wenn Sie ein Angebot anfordern oder eine Bestellung aufgeben möchten, legen Sie stattdessen die gewünschten Produkte in Ihren Warenkorb und fordern Sie dann ein Angebot oder eine Bestellung an aus dem Warenkorb. Es ist schneller, billiger und Sie können von den verfügbaren Rabatten und anderen Vorteilen profitieren.